iCeutica Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Investors
-
1
iCeutica General Information
Description
Manufacturer and provider of branded medicines. The company offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds.
Contact Information
Website
www.iceutica.comCorporate Office
- One Kew Place
- 150 Rouse Boulevard, Navy Yard Corporate Center
- Philadelphia, PA 19112
- United States
Corporate Office
- One Kew Place
- 150 Rouse Boulevard, Navy Yard Corporate Center
- Philadelphia, PA 19112
- United States
iCeutica Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 28-Apr-2011 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series D) | 16-Mar-2011 | Completed | Clinical Trials - Phase 3 | |||
| 3. Later Stage VC | 08-Jul-2010 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 30-Jun-2007 | $1.09M | $2.09M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 21-Jun-2005 | $1M | $1M | Completed | Product Development |
iCeutica Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 2,325,000 | $0.001000 | $0.05 | $1 | $1 | 1x | $1 | 47.8% |
iCeutica Comparisons
Industry
Financing
Details
iCeutica Competitors (5)
One of iCeutica’s 5 competitors is OncBioMune Pharmaceuticals, a Corporate Backed or Acquired company based in Baton Rouge, LA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OncBioMune Pharmaceuticals | Corporate Backed or Acquired | Baton Rouge, LA | ||||
| Alkermes | Formerly VC-backed | Dublin, Ireland | ||||
| ReveraGen BioPharma | Formerly VC-backed | Rockville, MD | ||||
| BioDelivery Sciences International | Private Equity-Backed | Raleigh, NC | ||||
| Novartis | Corporation | Basel, Switzerland |
iCeutica Patents
iCeutica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2016044701-A1 | Abiraterone acetate formulation and methods of use | Inactive | 18-Sep-2014 | ||
| US-20230414630-A1 | Novel formulation of meloxicam | Inactive | 09-Jun-2014 | ||
| US-20150157646-A1 | Abiraterone steroid formulation | Inactive | 27-Sep-2013 | ||
| AU-2014293193-A1 | Formulation of metaxalone | Inactive | 22-Jul-2013 | ||
| CA-2918908-A1 | Formulation of metaxalone | Inactive | 22-Jul-2013 | C07D263/24 |
iCeutica Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| PIPV Capital | PE/Buyout | Minority |
iCeutica FAQs
-
When was iCeutica founded?
iCeutica was founded in 2003.
-
Where is iCeutica headquartered?
iCeutica is headquartered in Philadelphia, PA.
-
What industry is iCeutica in?
iCeutica’s primary industry is Drug Discovery.
-
Is iCeutica a private or public company?
iCeutica is a Private company.
-
What is iCeutica’s current revenue?
The current revenue for iCeutica is .
-
How much funding has iCeutica raised over time?
iCeutica has raised $5.67M.
-
Who are iCeutica’s investors?
PIPV Capital has invested in iCeutica.
-
Who are iCeutica’s competitors?
OncBioMune Pharmaceuticals, Alkermes, ReveraGen BioPharma, BioDelivery Sciences International, and Novartis are competitors of iCeutica.
-
When was iCeutica acquired?
iCeutica was acquired on 28-Apr-2011.
-
Who acquired iCeutica?
iCeutica was acquired by Iroko Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process